Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Aug;83(2):502-583.
doi: 10.1016/j.jhep.2025.03.018. Epub 2025 May 10.

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

European Association for the Study of the Liver  1
Collaborators, Affiliations
Practice Guideline

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

European Association for the Study of the Liver. J Hepatol. 2025 Aug.

Abstract

The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directions. Chronic HBV remains a global health challenge, with over 250 million individuals affected and significant mortality due to cirrhosis and hepatocellular carcinoma. These guidelines emphasise the importance of early diagnosis, risk stratification based on viral and host factors, and tailored antiviral therapy. Attention is given to simplified algorithms, vaccination, and screening to support global HBV elimination targets. The guidelines also discuss emerging biomarkers and evolving definitions of functional and partial cure. Developed through literature review, expert consensus, and a Delphi process, the guidelines aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Pietro Lampertico has served on the Advisory Board/Speaker Bureau for Roche Pharma/Diagnostics, Gilead Sciences, GSK, AbbVie, Janssen, Myr, Eiger, Antios, Aligos, Vir, Grifols, Altona, and Roboscreen. Testoni Barbara has received research funding from Aligos, Assembly Biosciences, Bluejay Therapeutics and Beam Therapeutics; has received fees for expert testimony from the International Hepatology Education Program; and has a patent pending with Beam Therapeutics. Francesco Paolo Russo has held lectures for Gilead Sciences, AbbVie, Biotest, Grifols, and Johnson and Johnson, received support for attending meetings from Gilead Sciences and Biotest, received funding from Gilead Sciences, served as an advisory board member for GSK, Gilead Sciences and AbbVie. Lisa Sandmann has received lecture honoraria and personal fees from Falk Pharma e.V., Gilead Sciences and Roche, and travel support from AbbVie and Gilead Sciences. Jerzy Jaroszewicz has held lectures and obtained advisory grants from AbbVie, Roche, Gilead Sciences, Grifols, GSK, MSD, Novo Nordisk, and Novartis. Grace L Wong has served as an advisory committee member for AstraZeneca, Gilead Sciences, GSK, Janssen and Virion Biotherapeutics; as a speaker for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GSK, Janssen, and Roche. She has also received research grants from Gilead Sciences. Sabela Lens has served on the Speaker Bureau/Advisory Board for Gilead Sciences, AbbVie, GSK and Roche; and received research grants from Gilead Sciences. Markus Cornberg has held lectures for AbbVie, Gilead Sciences, MSD and Falk Foundation and served as an advisory board member for AbbVie, AiCuris, AstraZeneca, Gilead Sciences, GSK, Roche. Patrick Kennedy has served as an advisor/speaker for Gilead Sciences, GSK, Janssen, Abbott, Aligos, Assembly Bioscience and Bluejay Therapeutics. He has also received research grants from Gilead Sciences and Vir Biotechnology. Maud Lemoine has received consultant fees from Abbott, Cepheid, Gilead Sciences, ViiV healthcare and GSK. Please refer to the accompanying ICMJE disclosure forms for further details.

References

Publication types

MeSH terms

Substances

LinkOut - more resources